Pulmonary atelectasis caused by pneumoperitoneum and mechanical ventilation is further aggravated in obese patients. All rights reserved.Obese patients undergoing general anesthesia and mechanical ventilation during laparoscopic abdominal surgery commonly have a higher incidence of postoperative pulmonary complications (PPCs), due to factors such as decreasing oxygen reserve, declining functional residual capacity, and reducing lung compliance. National Key R&D Program of China, National Science and Technology Major Project, and CanSino Biologics.Ĭopyright © 2020 Elsevier Ltd. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. No serious adverse event was noted within 28 days post-vaccination. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. The most common injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly reported systematic adverse reactions were fever (50 ), fatigue (47 ), headache (42 ), and muscle pain (18. At least one adverse reaction within the first 7 days after the vaccination was reported in 30 (83%) participants in the low dose group, 30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. All enrolled participants were included in the analysis. Of them, 108 participants (51% male, 49% female mean age 36♳ years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. This study is registered with, NCT04313127.īetween March 16 and March 27, 2020, we screened 195 individuals for eligibility. T-cell responses were assessed by enzyme-linked immunospot and flow-cytometry assays. Specific antibodies were measured with ELISA, and the neutralising antibody responses induced by vaccination were detected with SARS-CoV-2 virus neutralisation and pseudovirus neutralisation tests. Safety was assessed over 28 days post-vaccination. The primary outcome was adverse events in the 7 days post-vaccination. Healthy adults aged between 18 and 60 years were sequentially enrolled and allocated to one of three dose groups (5 × 10 10, 1 × 10 11, and 1♵ × 10 11 viral particles) to receive an intramuscular injection of vaccine. We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. Electronic address: vaccine to protect against COVID-19 is urgently needed. Electronic address: 11 Beijing Institute of Biotechnology, Beijing, China.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |